Abstract 306P
Background
The optimal therapy for adenocarcinoma of the head and neck with distant metastasis is very limited and controversial. Although antiangiogenic therapy is effective in advanced lung, colon, hepatic, and renal carcinomas, limited is known about its value in the carcinoma of the head and neck. Apatinib, an oral, highly potent tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2), has been proven to be effective for the treatment of a broad range of advanced solid tumors. This prospective phase II study (NCT02989259) aims to investigate the efficacy and safety of apatinib in heavily pretreated patients with metastatic adenocarcinoma of the head and neck.
Methods
This study enrolled patients with adenocarcinoma of the head and neck, who failed in the metastatic setting at least one prior chemotherapy regimen. The primary end point was progression free survival (PFS). Secondary end points included objective response rate, disease control rate, overall survival (OS), and safety. Patients were treated with apatinib 500 mg daily until disease progression or the occurrence of intolerable toxicity. Efficacy was assessed every 8 weeks.
Results
From December 2016 to January 2019, twenty patients were enrolled, including 13 males and 7 females, with a median age of 61 years (26-79). The median number of previous chemotherapy regimens for the metastatic diseases was 2 (1-3). Partial response was achieved by 5 (25%) patients and stable disease exhibited by 14 (70%) patients.The median PFS and OS were 7.5 and 11.0 months, respectively. The most common adverse events (AEs) of all grade were secondary hypertension (n = 16), proteinuria(n = 10), hyperbilirubinemia (n = 10), nausea (n = 6), fatigue (n = 5) and hand-foot syndrome (n = 4). Grade 3/4 AEs were hypertension (n = 4), oral microsites (n = 3), and thrombocytopenia (n = 1). No grade 4 or 5 AE was observed in the study.
Conclusions
Our results indicated that apatinib exhibited objective efficacy in heavily pretreated, metastatic adenocarcinoma of the head and neck with a manageable toxicity profile. Apatinib can be considered as a treatment option for adenocarcinoma of the head and neck with metastatic diseases.
Clinical trial identification
The trial protocol number is NCT02989259. And release date is December 2016.
Editorial acknowledgement
Legal entity responsible for the study
CAMS & PUMC, National Cancer Center, Cancer Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract